Navigation Links
Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
Date:10/6/2010

eding that may result from the Arbitration Demand. Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation
statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.  Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
2. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
3. Angiotech Pharmaceuticals Announces Conference Call and Webcast
4. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
6. Angiotech Pharmaceuticals Announces Conference Call and Webcast
7. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
8. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
9. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
10. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
11. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  EMD ... Merck KGaA, Darmstadt, Germany , ... Vice President, Head of Global Clinical Development.  Dr. ... expertise, including experience in Oncology and Immunology. She ... ability, having served as a Vice President in ...
(Date:4/16/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... in new orphan drug indications, today announced that the ... as a clinical trial site for the ongoing, multicenter ... glioblastoma multiforme (GBM), the most common and deadly form ...
(Date:4/16/2015)... , April 16, 2015  Northwest Biotherapeutics, Inc. ... company developing non-toxic DCVax® personalized immune therapies for ... in the Loncar Cancer Immunotherapy Index (LCINDX), a ... track the immunotherapy field within the biotechnology space.  ... "the top 25 companies" in the immunotherapy space, ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... ... delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields , ... Oceanside, CA (PRWEB) April 26, ... and the market leader in solid support for oligonucleotide synthesis, will be launching its ...
... computers are static. In our brains, information processing ... international research team from Japan and Michigan Technological ... evolution in an organic molecular layer that can ... a brain-like "evolutionary circuit" has been realized. ...
... SHANGHAI , April 23 /PRNewswire-Asia/ -- ... that it filed its annual report on Form 20-F for,the ... and Exchange Commission.,The annual report can be accessed on WuXi ... WuXi,PharmaTech will provide a hard copy of its annual report ...
Cached Biology Technology:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 2Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 3Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 4WuXi PharmaTech Files 2009 Annual Report on Form 20-F 2
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
... successfully being used in clinical trials to treat patients with ... die, it also forces them to release pro-inflammatory chemokines and ... attack the disease. New research published by BioMed Central,s open ... infected cancer cells secrete proteins which, even when isolated, result ...
... Variations in skin color provide one of the best ... body and should be used to teach evolution in schools, ... level of interest in skin color and for teachers, that ... Nina Jablonski, professor and head, Department of Anthropology, Penn State. ...
Cached Biology News:Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4Skin color: Handy tool for teaching evolution 2Skin color: Handy tool for teaching evolution 3
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: